Silver Cross Hospital ∙ 1900 Silver Cross Blvd ∙ New Lenox, IL 60451 ∙ 815-300-7130 ∙ Fax 815-300-7917



Medic Class

Area CE/Events

System CME

Silver Cross CTC




System Entry

Good Standing Ltr

Change of System


Region 7 SMOs

System Policies


EMS Links


Buy Micardis HCT (Telmisartan, Hctz) tablets online

How and where to order Telmisartan with Hydrochlorothiazide (Micardis HCT) 40 mg / 12.5 mg tablets or capsules online:

Prices:from $1.30 per pill
Discount:5% coupon: 5OFF
Forms:Micardis HCT (Telmisartan, Hctz) 40 mg / 12.5 mg tablets
Quantity:30-360 pills
Type:Telmisartan/HCT brand, Micardis HCT generic
Payment:Visa, Mastercard, AmEx, Bitcoin
Delivery:Standard airmail and trackable courier service
Shipping:Worldwide, including USA, UK, Europe, Canada, Australia

Indications and usage:

Micardis HCT (Telmisartan and Hydrochlorothiazide) tablets are indicated for the treatment of hypertension (high blood pressure). This fixed dose combination is not indicated for initial therapy.

Dosage and administration:

The usual starting dose of telmisartan is 40 mg once a day; blood pressure response is dose related over the range of 20-80 mg. Patients with depletion of intravascular volume should have the condition corrected or telmisartan tablets should be initiated under close medical supervision. Patients with biliary obstructive disorders or hepatic insufficiency should have treatment started under close medical supervision.

Hydrochlorothiazide is effective in doses of 12.5 mg to 50 mg once daily.

To minimize dose-independent side effects, it is usually appropriate to begin combination therapy only after a patient has failed to achieve the desired effect with monotherapy. The side effects of telmisartan are generally rare and apparently independent of dose; those of hydrochlorothiazide are a mixture of dose-dependent phenomena (primarily hypokalemia) and dose-independent phenomena (e.g., pancreatitis), the former much more common than the latter. Therapy with any combination of telmisartan and hydrochlorothiazide will be associated with both sets of dose-independent side effects.

Micardis HCT (Telmisartan/Hctz) tablets may be administered with other antihypertensive agents.

This medication may be administered with or without food.

Dosage forms and strengt:

Micardis HCT tablets are available in three strengths as biconvex two-layered, oblong-shaped, uncoated tablets in three combinations of 40 mg/12.5 mg, 80 mg/12.5 mg and 80 mg/25 mg telmisartan and hydrochlorothiazide, respectively. The hydrochlorothiazide layer is red in the 40 mg/12.5 mg and 80 mg/12.5 mg tablets, and yellow in the 80 mg/25 mg tablets, and all are unmarked. The telmisartan layer for all three strengths is white, but may contain red specks in the 40 mg/12.5 mg and 80 mg/12.5 mg tablets and yellow specks in the 80 mg/25 mg tablets. The telmisartan layer is marked with the Boehringer Ingelheim logo and H4 for the 40 mg/12.5 mg dose strength, H8 for the 80 mg/12.5 mg dose strength and H9 for the 80 mg/25 mg dose strength.


Telmisartan Limited data are available with regard to overdosage in humans. The most likely manifestations of overdosage with telmisartan would be hypotension, dizziness and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation. If symptomatic hypotension should occur, supportive treatment should be instituted. Telmisartan is not removed by hemodialysis.


The most common signs and symptoms observed in patients are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias. The degree to which hydrochlorothiazide is removed by hemodialysis has not been established. The oral LD50 of hydrochlorothiazide is greater than 10 g/kg in both mice and rats.


Micardis HCT tablets are contraindicated in patients with known hypersensitivity (e.g., anaphylaxis or angioedema) to telmisartan, hydrochlorothiazide, or any other component of this product.

Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.

Warnings and precautions:

  • Fetal toxicity: use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.
  • Hypotension in volume-depleted patients: initiation of antihypertensive therapy in patients whose renin-angiotensin system are activated such as patients who are intravascular volume- or sodium-depleted, e.g., in patients treated vigorously with diuretics, should only be approached cautiously.
  • Thiazide diuretics may cause an exacerbation or activation of systemic lupuserythematosus.
  • Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history.
  • Systemic lupus erythematosus: thiazide diuretics have been reported to cause exacerbation or activation of systemic lupus erythematosus.
  • Lithium generally should not be given with thiazides.
  • Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma.
  • Serum electrolytes: in controlled trials using the telmisartan/hydrochlorothiazide combination treatment, no patient administered 40/12.5 mg, 80/12.5 mg or 80/25 mg had a decrease in potassium ?1.4 mEq/L, and no patient experienced hyperkalemia.

    Adverse reactions, side effects:

    The most common side effects of Micardis HCT pills include upper respiratory tract infections, dizziness, feeling tired, flu-like symptoms, back pain, diarrhea, nausea.

    To report suspected side effects of Micardis HCT (Telmisartan, Hctz) tablets contact Boehringer Ingelheim pharmaceutical company or your local FDA.

    Drug interactions:

  • Alcohol, barbiturates, or narcotics: potentiation of orthostatic hypotension may occur.
  • Antidiabetic drugs (oral agents and insulin): dosage adjustment of the antidiabetic drug may be required.
  • Cholestyramine and colestipol resins: absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively.
  • Corticosteroids, ACTH: intensified electrolyte depletion, particularly hypokalemia.
  • Digoxin: when telmisartan was co-administered with digoxin, median increases in digoxin peak plasma concentration (49%) and in trough concentration (20%) were observed.
  • Lithium: reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors. Lithium containing medications should not generally be given with diuretics. In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
  • Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): in patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including telmisartan, may result in deterioration of renal function, including possible acute renal failure.
  • Other antihypertensive drugs: additive effect or potentiation.
  • Pressor amines (e.g., norepinephrine): possible decreased response to pressor amines but not sufficient to preclude their use.
  • Ramipril and Ramiprilat: co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively.
  • Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine): possible increased responsiveness to the muscle relaxant.
  • Warfarin: telmisartan administered for 10 days slightly decreased the mean warfarin trough plasma concentration; this decrease did not result in a change in International Normalized Ratio (INR).

    Related medications:

  • Nifedipine (Adalat)
  • Zopiclone tablets

    Use in specific populations:

    Pediatric: telmisartan pharmacokinetics have not been investigated in patients < 18 years of age.

    Geriatric: the pharmacokinetics of telmisartan do not differ between the elderly and those younger than 65 years.

    Gender: plasma concentrations of telmisartan are generally 2-3 times higher in females than in males. In clinical trials, however, no significant increases in blood pressure response or in the incidence of orthostatic hypotension were found in women. No dosage adjustment is necessary.

    Renal insufficiency: renal excretion does not contribute to the clearance of telmisartan. Based on modest experience in patients with mild-to-moderate renal impairment (creatinine clearance of 30-80 mL/min, mean clearance approximately 50 mL/min), no dosage adjustment is necessary in patients with decreased renal function. Telmisartan is not removed from blood by hemofiltration.

    Hepatic insufficiency: in patients with hepatic insufficiency, plasma concentrations of telmisartan are increased, and absolute bioavailability approaches 100%.

    Information for patients:


    Female patients of childbearing age should be told about the consequences of exposure to Micardis HCT during pregnancy. Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible.

    Symptomatic hypotension

    A patient receiving Telmisartan/Hctz (Micardis HCT) tablets should be cautioned that lightheadedness can occur, especially during the first days of therapy, and that it should be reported to the prescribing doctor. The patients should be told that if syncope occurs, this medicine should be discontinued until the physician has been consulted.

    All patients should be cautioned that inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to an excessive fall in blood pressure, with the same consequences of lightheadedness and possible syncope.

    Potassium supplements

    A patient receiving Micardis HCT pills should be told not to use potassium supplements or salt substitutes that contain potassium without consulting the prescribing physician.

    Where to buy hydrochlorothiazide and telmisartan online:

    To purchase Micardis HCT (Telmisartan, Hydrochlorothiazide) tablets from reliable online pharmacies and drugstores at low prices please use resources described above on this webpage.

    Here is a list of popular medications containing telmisartan with hydrochlorothiazide as main active pharmaceutical ingredients; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:

    Trade name of the drug Pharmaceutical forms and doses Companies
    Micardis HCT
  • Tablets; Oral; Hydrochlorothiazide 12.5 mg; Telmisartan 40 mg
  • Tablets; Oral; Hydrochlorothiazide 12.5 mg; Telmisartan 80 mg
  • Tablets; Oral; Hydrochlorothiazide 25 mg; Telmisartan 80 mg
  • Boehringer Ingelheim
  • Pritor Plus
  • Tablets; Oral; Hydrochlorothiazide 12.5 mg; Telmisartan 40 mg
  • Tablets; Oral; Hydrochlorothiazide 12.5 mg; Telmisartan 80 mg
  • Tablets; Oral; Hydrochlorothiazide 25 mg; Telmisartan 80 mg
  • Bayer
  • GlaxoSmithKline
  • Telma-H
  • Tablets; Oral; Hydrochlorothiazide 12.5 mg; Telmisartan 40 mg
  • Tablets; Oral; Hydrochlorothiazide 12.5 mg; Telmisartan 80 mg
  • Glenmark Pharmaceuticals
  • Zoltan Care

    Copyright © 2006 - 2023 Will Grundy Silver Cross Emergency Medical Services System. All Rights Reserved.